Carregant...
No increase in breast cancer recurrence with concurrent use of tamoxifen and some CYP2D6-inhibiting medications
Tamoxifen reduces recurrence risk among women treated for estrogen receptor-positive breast cancer. Its effectiveness partly depends on metabolic activation via cytochrome P450 2D6 (CYP2D6). Some medications compromise CYP2D6 activity and may lower plasma concentrations of active tamoxifen metabolit...
Guardat en:
| Autors principals: | , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2009
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2742564/ https://ncbi.nlm.nih.gov/pubmed/19690182 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1055-9965.EPI-09-0516 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|